Options for pharmacological treatment of refractory bipolar depression

Current Psychiatry Reports

Volumn 16, Issue 2, 2014, Pages

  Tondo, Leonardo ^a,c   Vázquez, Gustavo H ^a,d   Baldessarini, Ross J ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Lucio Bini Mood Disorder Centers   (Italy)

^d UNIVERSITY OF PALERMO   (Argentina)

Author keywords

Amphetamine; Aripiprazole; Bipolar disorder; Bupropion; Creatine; Depression; Inositol; Ketamine; Ketoconazole; Lamotrigine; Methylphenidate; Modafinil; N acetylcysteine; Pramipexole; Quetiapine; Risperidone, Stimulants; Treatment resistance; Tri iodothyronine

Indexed keywords

ANTIDEPRESSANT AGENT;

BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); HUMAN; REVIEW;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84891896732     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-013-0431-y     Document Type: Article

References (50)

1. Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143-57.
2. Judd LL, Akiskal HS, Schettler PJ, et al. Long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6): 530-7. (Pubitemid 34602935)
3. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003;64(6): 680-90. (Pubitemid 36750146)
4. Joffe RT, MacQueen GM, Marriott M, et al. Prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord. 2004;6(1): 62-6. (Pubitemid 38256505)
5. Paykel ES, Abbott R, Morriss R, et al. Sub-syndromal and syndromal symptoms in the longitudinal course of bipolar disorder. Br J Psychiatry. 2006;189(8): 118-23. (Pubitemid 44231269)
6. Baldessarini RJ, Salvatore P, Khalsa H-MK, et al.Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010;12(3): 264-70.
7. Vergunst FK, Fekadu A, Wooderson SC, et al. Longitudinal course of symptom severity and fluctuation in patients with treatment-resistant unipolar and bipolar depression. Psychiatry Res. 2013;207(3):143-9.
8. Baldessarini RJ, Tondo L, Visioli C. First-episode types in bipolar disorder: predictive associations with later illness. Acta Psychiatr Scand. 2013; in press.
9. Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9): 844-50. (Pubitemid 32979302)
10. Kessler U, Schoeyen HK, Andreassen OA, et al. Neurocognitive profiles in treatment-resistant bipolar I and bipolar II disorder depression. BMC Psychiatry. 2013;13(4):105.
11. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; [Epub ahead of print (28 Aug)].
12. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: review and meta-analysis of the evidence. Bipolar Disord. 2010;12(1): 1-9.
13. Colom F, Vieta E, Daban C, et al. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord. 2006;93(1-3): 13-7. (Pubitemid 43816068)
14. Baldessarini RJ, Undurraga J, Vázquez GH, et al. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand. 2012;125(4): 293-302.
15. Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand. 2009;120(6): 429-40.
16. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am. 1996;19(2): 215-36. (Pubitemid 26184100)
17. Schosser A, Serretti A, Souery D, et al. European Group for the Study of Resistant Depression (GSRD)-where have we gone so far: review of clinical and genetics findings. Eur Neuropsychopharmacol. 2012;22(7):453-68.
18. Li C-T, Bai Y-M, Huang Y-L, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar depression: cohort study. Br J Psychiatry. 2012;200(1):45-51.
19. Vázquez GH, Tondo L, Baldessarini RJ. Comparison of antidepressant responses in patients with bipolar vs. unipolar depression: meta-analytic review. Pharmacopsychiatry. 2011;44(1): 21-6.
20. Tondo L, Baldessarini RJ, Vázquez GH, et al. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand. 2013;127(5):355-64.
21. Vázquez GH, Tondo L, Undurraga J, et al. Overview of antidepressant treatment in bipolar depression: critical commentary. Intl J Neuropsychopharmacol. 2013;16(7): 1673-85.
22. Vázquez GH, Tondo L, Undurraga J, et al. Pharmacological treatment for bipolar depression. Adv Psychiatr Treatment. 2013; in press.
23. Goodwin GM, Consensus Group. Evidence-based guidelines for treating bipolar disorder: revised, second edition-recommendations of the British Association of Psychopharmacology. J Psychopharmacol. 2009;23(4): 346-88.
24. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of guidelines for management of patients with bipolar disorder. Bipolar Disord. 2013;15(1):1-44.
25. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. International Society for Bipolar Disorders (ISBD) task-force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; in press.
26. Goodwin GM. Bipolar depression and treatment with antidepressants. Br J Psychiatry. 2012;200(1): 5-6.
27. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161(3): 564-6. (Pubitemid 38326114)
28. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163(2): 210-6. (Pubitemid 44480839)
29. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164(8): 1242-9. (Pubitemid 47292414)
30. Diazgranados N, Ibrahim L, Brutsche NE, et al. Randomized addon trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8): 793-802.
31. Zarate Jr CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: randomized controlled add-on trial. Biol Psychiatry. 2012;71(5): 939-46.
32. Sienaert P, Lambrichts L, Dols A, et al. Evidence-based treatment strategies for treatment-resistant bipolar depression: systematic review. Bipolar Disord. 2013;15(1): 61-9.
33. Brown ES, Bobadilla L, Rush AJ. Ketoconazole in bipolar patients with depressive symptoms: case series and literature review. Bipolar Disord. 2001;3(1): 23-9. (Pubitemid 32219845)
34. Erfurth A, Michael N, Stadtland C, Arolt V. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology. 2002;45 Suppl 1: 33-6. (Pubitemid 34224976)
35. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatmentresistant depression: an extended follow-up. Depress Anxiety. 2004;20(3): 131-8. (Pubitemid 39587564)
36. Ketter TA, Wang PW, Chandler RA, et al. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry. 2006;18(3): 169-72. (Pubitemid 44576438)
37. Roitman S, Green T, Osher Y, et al. Creatine monohydrate in resistant depression: preliminary study. Bipolar Disord. 2007;9(7): 754-8. (Pubitemid 350042411)
38. Nierenberg AA. Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. Psychother Psychosom. 2009;78(6): 391-3.
39. Kelly T, Lieberman DZ. The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. J Affect Disord. 2009;116(3): 222-6.
40. Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr Scand. 2010;121(4): 308-14.
41. Ahn YM, Nam JY, Culver JL, et al. Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression. Ann Clin Psychiatry. 2011;23(1): 17-24.
42. Schaffer LC, Schaffer CB, Miller AR, et al. Open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment-resistant bipolar disorder. J Affect Disord. 2013;147(1-3): 407-10.
43. Thase ME, Jonas A, Khan A. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebocontrolled studies. J Clin Psychophrmacol. 2008;28(1): 13-20.
44. Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled trials of mood-stabilizers and second-generation antipsychotics. Pharmacopsychiatry 2013; in press.
45. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. Psychiatry. 2011;72(3): 356-66.
46. Lorenzo LS, Vázquez GH, Zaratiegui RM, et al. Characteristics of bipolar disorder patients given antidepressants. Hum Psychopharmacol. 2012;27(5): 486-91.
47. Undurraga J, Baldessarini RJ, Valenti M, et al. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord. 2012;139(1): 89-93.
48. Tondo L, Vázquez GH, Baldessarini RJ. Mania associated with antidepressant-treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404-14.
49. Kessler U, Vaaler AE, Schøyen H, et al. Study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder. BMC Psychiatry. 2010;10(2):16.
50. Baldessarini RJ. Chemotherapy in Psychiatry. 3rd ed. New York: Springer Press; 2013.